| 06/29/2026 1:30 PM | AstraZeneca (901832) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/29/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 5:05 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/16/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 5:52 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:06 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/29/2026 5:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/28/2026 1:29 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
| 05/27/2026 5:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:09 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for AZNCF and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.
|
| 05/26/2026 6:17 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 6:02 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 9:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:42 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 8:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/14/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/08/2026 3:05 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 9:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 6:23 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 10:32 AM | AstraZeneca (901832) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/28/2026 6:31 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 5:29 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/23/2026 5:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/21/2026 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 6:03 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/09/2026 12:01 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/08/2026 1:20 PM | AstraZeneca (901832) Subject NEW YORK STOCK EXCHANGE LLC (876661) Filed by | Form 25-NSE | |
| 04/02/2026 8:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 9:30 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/31/2026 6:48 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 7:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/20/2026 6:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/19/2026 6:51 PM | AstraZeneca (901832) Issuer Sharma Mani (2122411) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 7:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 7:07 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/10/2026 6:37 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 7:11 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Stranded On The Flood Plains of History (Ad) The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War.
Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving.
Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar. Read Porter's full briefing and get the ticker names today |
| 03/06/2026 6:43 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/06/2026 6:50 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/04/2026 8:14 AM | AstraZeneca (901832) Filer | Form CERT | |
| 03/03/2026 3:01 PM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 8-A12B | |
| 03/02/2026 11:00 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/26/2026 7:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 9:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/25/2026 7:30 AM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 02/24/2026 5:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/24/2026 5:45 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/20/2026 5:57 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/10/2026 10:55 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/06/2026 8:48 AM | AstraZeneca (901832) Filed by Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject | Form SCHEDULE 13D/A | |
| 02/06/2026 8:54 AM | AstraZeneca (901832) Filed by Monopar Therapeutics (1645469) Subject | Form SCHEDULE 13G/A | |
| 02/03/2026 2:21 PM | AstraZeneca (901832) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/03/2026 6:01 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 12:26 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 6:51 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 6:25 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/30/2026 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 7:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/22/2026 3:28 PM | AstraZeneca (901832) Filer | Form CERT | |
| 01/22/2026 3:22 PM | AstraZeneca Finance LLC (1862005) Filer AstraZeneca (901832) Filer | Form 8-A12B | |
| 01/22/2026 3:14 PM | AstraZeneca (901832) Filer | Form CERT | |
| 01/20/2026 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/08/2026 5:04 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/02/2026 11:24 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 6:47 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 6:02 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/19/2025 7:35 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/16/2025 5:42 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/16/2025 5:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 12:48 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/01/2025 10:40 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/01/2025 10:47 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 5:27 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/20/2025 7:31 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/17/2025 11:52 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/14/2025 9:12 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/12/2025 4:35 PM | AstraZeneca (901832) Subject SARIN ARADHANA (1729110) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/10/2025 11:15 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/06/2025 6:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/03/2025 12:31 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/03/2025 12:22 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/03/2025 11:36 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2025 9:10 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2025 7:02 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/22/2025 7:07 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/20/2025 6:12 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Iran War Shock: What I Was Told In That Private Meeting (Ad) You’re Being LIED To About The Iran War
Forget EVERYTHING you’ve heard about the Iran war.
Especially the reasons why we’re bombing the country. Because THIS is the real reason. |
| 10/20/2025 5:47 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/14/2025 5:05 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/07/2025 5:30 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/06/2025 6:18 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/01/2025 9:19 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/29/2025 5:59 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/29/2025 6:05 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/29/2025 5:08 AM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/25/2025 12:27 PM | AstraZeneca (901832) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |